A Practical and Total Synthesis of Pasireotide: Synthesis of Cyclic Hexapeptide via a Three-Component Condensation

A Practical and Total Synthesis of Pasireotide: Synthesis of Cyclic Hexapeptide via a Three-Component Condensation

Pasireotide is a multi-receptor ligand somatostatin analogue approved for medical treatment of Cushing’s disease and acromegaly. The liquid-phase total synthesis of pasireotide-a 18-membered cyclic hexapeptide-was achieved by the 3 + 2 + 1 strategy, and the Pro<sup>1</sup>-Phe&...

Full description

Bibliographic Details
Main Authors:	Chunying Ma, Miao Chen, Weiming Chu, Jiayi Tao, Delong Kong, Mengmeng Zhang, Wenhua Feng
Format:	Article
Language:	English
Published:	MDPI AG 2019-06-01
Series:	Molecules
Subjects:	pasireotide liquid-phase synthesis BSA/NHS cyclic hexapeptide
Online Access:	https://www.mdpi.com/1420-3049/24/11/2185

Similar Items

Antitumor Cyclic Hexapeptides from Rubia Plants: History, Chemistry, and Mechanism (2005–2011)
by: Si Meng Zhao, et al.
Published: (2011-12-01)

Bistratamides M and N, Oxazole-Thiazole Containing Cyclic Hexapeptides Isolated from Lissoclinum bistratum Interaction of Zinc (II) with Bistratamide K
by: Carlos Urda, et al.
Published: (2017-07-01)

A New Cyclic Hexapeptide and a New Isocoumarin Derivative from the Marine Sponge-Associated Fungus Aspergillus similanensis KUFA 0013
by: Chadaporn Prompanya, et al.
Published: (2015-03-01)

Production of Atosiban’s Key Intermediate Pentapeptide: Synthetic Approaches to the Development of a Peptide Synthesis with Less Racemization and Simplifier Purification Process
by: Chunying Ma, et al.
Published: (2022-03-01)

A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment
by: Xiucheng Yang, et al.
Published: (2019-01-01)

Crosstalk of Cancer Signaling Pathways by Cyclic Hexapeptides and Anthraquinones from <i>Rubia cordifolia</i>
by: Premalatha Balachandran, et al.
Published: (2021-01-01)

Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01)

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
by: Feun LG, et al.
Published: (2018-01-01)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
by: Mônica R Gadelha, et al.
Published: (2020-12-01)

Pasireotide after Surgery for Persistent Cushing’s Disease
by: Dan Nicolae PADURARU, et al.
Published: (2019-12-01)

Total Synthesis of a Reversed-Bacicyclin Using a Combination of Solid- and Solution-Phase Methods
by: Rani Maharani, et al.
Published: (2022-07-01)

Quantitation of Acetyl Hexapeptide-8 in Cosmetics by Hydrophilic Interaction Liquid Chromatography Coupled to Photo Diode Array Detection
by: Vasiliki Raikou, et al.
Published: (2021-08-01)

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
by: Rouland A, et al.
Published: (2021-02-01)

New Cytotoxic Cyclic Peptide from the Marine Sponge-Associated Nocardiopsis sp. UR67
by: Alyaa Hatem Ibrahim, et al.
Published: (2018-08-01)

N-Terminal Acetylation and C-Terminal Amidation of <i>Spirulina platensis</i>-Derived Hexapeptide: Anti-Photoaging Activity and Proteomic Analysis
by: Qiaohui Zeng, et al.
Published: (2019-09-01)

Energy Landscapes and Heat Capacity Signatures for Monomers and Dimers of Amyloid-Forming Hexapeptides
by: Nicy, et al.
Published: (2023-06-01)

Successful debulking of plurihormonal pituitary macroadenoma with long‐acting pasireotide and dopamine agonist combination therapy
by: Terri W. Jerkins, et al.
Published: (2019-03-01)

Controversy of Peptide Cyclization from Tripeptide
by: Chung-Yin Lin, et al.
Published: (2021-01-01)

Rapid response of Nelson’s syndrome to pasireotide in radiotherapy-naive patient
by: Xin He, et al.
Published: (2020-11-01)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
by: A. Ciresi, et al.
Published: (2018-01-01)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
by: Richard A. Feelders, et al.
Published: (2023-10-01)

Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation
by: Christiaan F. Mooij, et al.
Published: (2021-12-01)

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
by: Przemysław Witek, et al.
Published: (2021-03-01)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
by: Nelma Veronica Marques, et al.
Published: (2023-09-01)

Loss of efficacy of pasireotide after its re-administration: is there a reason why?
by: Stylianos Mandanas, et al.
Published: (2016-12-01)

Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature
by: Hasan Husni, et al.
Published: (2022-03-01)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
by: Hélène Lasolle, et al.
Published: (2019-10-01)

Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
by: Alessandro Mondin, et al.
Published: (2022-07-01)

Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement
by: Sylvère Störmann, et al.
Published: (2024-02-01)

What Goes around Comes around-A Comparative Study of the Influence of Chemical Modifications on the Antimicrobial Properties of Small Cyclic Peptides
by: Margitta Dathe, et al.
Published: (2013-09-01)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
by: Soraya Puglisi, et al.
Published: (2020-02-01)

Pasireotide: a novel treatment for patients with acromegaly
by: Cuevas-Ramos D, et al.
Published: (2016-01-01)

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
by: Sandrine Oziel-Taieb, et al.
Published: (2022-04-01)

First total synthesis and biological evaluation of halolitoralin A
by: RAJIV DAHIYA, et al.
Published: (2007-02-01)

First total synthesis and biological evaluation of halolitoralin A
by: Dahiya Rajiv, et al.
Published: (2007-01-01)

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly
by: Jan-Shun Chang, et al.
Published: (2016-06-01)

P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs
by: Donatella Treppiedi, et al.
Published: (2022-05-01)

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
by: Mattia Barbot, et al.
Published: (2022-05-01)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
by: Mônica Gadelha, et al.
Published: (2020-02-01)

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer
by: Julie E. Bauman, et al.
Published: (2022-05-01)